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Abstract
Background: Arguments have continued for long
concerning low carbohydrate diet and calorie restriction
(calorie-restricted diet). Authors have reported clinical
studies of low carbohydrate diet on ketone bodies,
glucose variability and Morbus value so far.
Subjects and methods: Subjects are 28 patients with Type
2 diabetes mellitus, which were 20/8 (M/F) with 48.3 ±
13.9 years old with serum triglyceride more than 250
mg/dL on blood sampling with overnight fasting. They
were admitted for 14 days and the protocol was as
follows: 1) calorie-restricted diet on day 1 and 2, which
had 60% carbohydrates, 2) low carbohydrate diet on day
3-14 days which is so-called super-low carbohydrate diet
formula with 12% carbohydrates.
Results: Mean HbA1c was 8.0 ± 1.7% and mean fasting
glucose was 177 ± 52 mg/dL. Median data days 2 to 4
were 208 to 147 mg/dL in average glucose, 146 to 21 in
Morbus (M) value and 123 to 94.5 mg/day in urinary C-
peptide. Median data days 2 to 14 were 366 to 159 mg/dL
in Triglyceride, 46 to 42 mg/dL in HDL-C and 111 to 120
mg/dL in LDL-C. Remnant-like particle cholesterol on day 2
was 15.9 mg/dL in median. Significant correlations on day
2 were shown between Triglyceride and HDL-C (p<0.05),
Triglyceride and LDL-C (p<0.05). Remnant-like particle
cholesterol-C showed significant positive correlation with
Atherogenic Index (AI) and triglyceride (p<0.01),
significant negative correlation with HDL (p<0.05).
Significant correlations were shown on day 2 and 14 in
Triglyceride and LDL-C/HDL-C Ratio (p<0.01).
Discussion and conclusion: Decrease of blood glucose
indicated short effect of low carbohydrate diet only for 2
days from calorie restriction to low carbohydrate diet.
Apparent large decrease of M value would be useful for
clinical management and research. Analyses of
correlations among RLP-C, triglyceride, HDL-C, LDL-C, AI
and LDL-C/HDL-C Ratio would become the fundamental
data for clinical research and give the hint for research
direction in the future.
Keywords: Hypertriglycemia; Low carbohydrate diet;
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Abbreviation:LCD: Low-Carbohydrate Diet; CRD: Calorie-
Restricted Diet; CR: Calorie Restriction; T2DM: Type 2
Diabetes Mellitus; T1DM: Type 1 Diabetes Mellitus; M
value: Morbus value; MAGE: Mean Amplitude of Glycemic
Excursions; IRI: Immuno-Reactive Insulin; CPR: C-Peptide
Immunoreactivity; HOMA-R: Homeostasis Model
Assessment-Insulin Resistance; HOMA-β: Homeostasis
Model Assessment of β-cell Function; HDL-C: High Density
Lipoprotein Cholesterol; LDL-C: Low Density Lipoprotein
Cholesterol; RLP-C: Remnant-Like Particle Cholesterol;
CVD: Cardiovascular Disease; CHD: Coronary Heart
Disease; CAD: Coronary Artery Disease; DAIS: Diabetes
Atherosclerosis Intervention Study; AUCs: Area Under the
Curves; AI: atherogenic Index; L/H ratio: LDL-C/HDL-C
Ratio
Introduction
For years, Low Carbohydrate Diet (LCD) has been more
prevalent and evaluated with clinical efficacy for various
disease and states. Recent reports have included various
evidence of LCD such as randomized controlled trials,
systematic review and meta-analyses [1-5].
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From the historical discussion of LCD and calorie restriction
(CR) diet (calorie restricted diet, CRD), Atkins and Bernstein
originally have begun to introduce LCD in European and North
American region [6,7]. Consecutively, clinical predominance of
LCD has been shown by investigators [8-13].
LCD has been recently applied widely to several diseases
and impaired states. They include metabolic syndrome (Met-
S), obesity, non-alcoholic fatty liver disease (NAFLD),
obstructive sleep apnea, diabetic nephropathy, cardiovascular
disease and hyperlipidemia [1,4,14-17]. Thus, broad
application of LCD would necessitate the integrated research
covering glucose and lipid metabolism.
On the other hand, the author have firstly introduced and
reported LCD for T2DM in Japan [18,19]. Subsequently, we
reported clinical studies of LCD in the light of elevated ketone
bodies, formular diet and Morbus (M) value [20-24].
In current study, we investigated the effect of LCD for the
patients with T2DM with high degree of hypertriglycemia, as
well as the influence and correlation for glucose and lipid
metabolism in short term.
Subjects and Methods
In this study, the subjects included 28 patients with Type 2
diabetes mellitus (T2DM), which were 20 males and 8 females.
They are 18-74 years old with 48.3 ± 13.9 (mean ± SD) yo. in
average, 50 yo. in the median value. The subjects included for
this study were selected who showed the serum level of
triglyceride more than 250 mg/dL, when the blood specimen
were withdrawn in overnight fasting for 12 hours.
They were admitted for 14-15 days for the educational
admission for treatment of T2DM, and received endocrine and
metabolic evaluation. The protocol of diet therapy was as
follows: 1) Calorie Restriction (CR) diet was provided on day 1
and 2, which had 60% carbohydrates, 25% lipids and 15%
protein with 1400 kcal/day. 2) Low Carbohydrate Diet (LCD)
was provided from 3 to 15 days, which had 12% carbohydrates,
64% lipids and 24% protein with 1400 kcal/day. 3) This LCD has
been so-called “super-LCD formula” in our clinical research for
LCD, which is one of the Very low-carbohydrate ketogenic diet
(VLCKD) by the definitions of LCD [13,18-20,23].
The evaluation for glucose and lipid metabolism was
performed as follows: 1) basal biomarkers measured for
research, 2) several biomarkers on day 2 and 14 such as
triglyceride, HDL-C and LDL-C, 3) daily profile of blood glucose
on day 2 (CR) and 4 (LCD), 4) Morbus (M) value calculated from
blood glucose, 5) correlations among several biomarkers
obtained.
Analysis method and M value
M value is the index representing both blood sugar level and
mean amplitude of glycemic excursions (MAGE) [25-28]. For
the glucose variability, daily profiles of blood glucose were
measured 7 times a day, and data were calculated for average
glucose level and Morbus (M) value. Morus (M) value has been
proposed for researching MAGE. This index has been
calculated as a logarithmic transformation of the deviation of
glycemia from an arbitrary assigned “ideal” glucose value, with
an expression of both the mean glucose value and the effect of
glucose swings [25-29].
M value is calculated by the formula as follows: M=MBS
+MW, where MW= (maximum blood glucose-minimum
glucose)/20; MBS=the mean of MBSBS; MBSBS=individual M-
value for each blood glucose value calculated as (absolute
value of [10 × log (blood glucose value/120)])3.
As to the interpretation of M value, the standard range is
<180, borderline is 180-320 and abnormal is >320. Adequate
sampling times a day have been argued for the detail and
precise evaluation of glucose variability and MAGE. There were
similar results on 7 times or 20 times of sampling per day
[25,28,30], showing similar result in comparison with
continuous glucose monitoring (CGM) [28,31,32].
Statistical analyses
In current study, data was represented as the mean ±
standard deviation (SD) and also represented median, quartile
of 25% and 75% in biomarkers. For statistical analyses,
correlation coefficients were calculated using Pearson or
Spearman test of the Microsoft Excel analytical tool, which is
four steps Excel Statistics 4th edition [33].
Intergroup comparisons were made using the Wilcoxon rank
sum test or the Bonferroni multiple comparisons (Lambert
method). A significance level of less than 5% obtained using a
two-tailed test was considered to be statistically significant.
Ethical considerations
This study was conducted in compliance with the ethical
principles of the Declaration of Helsinki and Japan’s Act on the
Protection of Personal Information along with the Ministerial
Ordinance on Good Clinical Practice (GCP) for Drug (Ordinance
of Ministry of Health and Welfare No. 28 of March 27, 1997).
No ethical committee meeting was held. Informed consent
was obtained from the subjects concerning this questionnaire.
The study was registered with UMIN #R000031211.
Results
Fundamental data
The basal data of the 28 patients were shown in Table 1.
The mean HbA1c was 8.0 ± 1.7%, and urinary C-peptide
excretion decreased from 123 mg/day to 94.5 mg/day in
average from day 2 (CR) to, day 4 (LCD).
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 Mean ± SD Median [25%-75%]
Subjects
Number 28 28
Sex (male/female) 20/8 20/8
Age (y.o.) 48.3 ± 13.9 50 (39.5-60)
Glucose (basal)
HbA1c (%) 8.0 ± 1.7 8.0 (6.5-9.4)
Fasting Glucose (mg/dL) 177 ± 51.7 172 (127-213)
IRI (μU/mL) 10.7 ± 7.9 7.4 (5.9-11.4)
HOMA-R 4.4 ± 3.4 3.6 (2.1-5.1)
HOMA-β 54.6 ± 74.6 29.0 (17.3-50.4)
Glucose (M value related)
Average glucose on day 2 (mg/dL) 214.7 ± 70.9 208 (148-279)
Average glucose on day 4 (mg/dL) 154.8 ± 44.2 147 (119-189)
M value on day 2 232 ± 233 146 (23.6-428)
M value on day 4 45.4 ± 57.9 21.0 (4.5-72.1)
Glucose (CPR excretion in urine)
Urinary CPR on day 2 (mg/day) 123 ± 61.2 118 (78.4-147)
Urinary CPR on day 4 (mg/day) 94.5 ± 41.9 97.5 (54.9-131)
Lipid Metabolism
Triglyceride on day 2 (mg/dL) 499 ± 357 366 (290-488)
Triglyceride on day 14 (mg/dL) 164 ± 83.6 159 (104-98)
HDL-C on day 2 (mg/dL) 45.4 ± 10.9 45.5 (38-50)
HDL-C on day 14 (mg/dL) 43.8 ± 10.0 42.0 (36.8-47.5)
LDL-C on day 2 (mg/dL) 117 ± 50.1 111 (80.3-139)
LDL-C on day 14 (mg/dL) 148 ± 51.1 120 (110-141)
RLP-C on day 2 (mg/dL) 20.1 ± 22.9 15.9 (9.2-21.1)
The results were expressed by the data of mean ± standard deviation and also median and [25%-75%] in left and right column, respectively.
Changes of glucose and lipid biomarkers
Average glucose from day 2 to day 4 decreased significant
difference statistically (p<0.05) (Figure 1). M value apparently
decreased from 2 to day 4, in which significant difference
could not calculated for large standard deviation (SD)
compared to average value.
Figure 1 The changes of average glucose and M value.
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Table 1 Basal data of the subjects.
Average glucose and M value decreased from day 2 to day 4
apparently. The former showed significant decrease (p<0.05).
The latter showed larger standard deviation compared to the
average level, and then significant difference could not
calculated. Maximum data of M value on day 2 was 783.
Triglyceride level apparently decreased from day 2 to day
14. The median value was from 366 mg/dL to 169 mg/dL
(Figure 2). HDL-C and LDL-C did not show significant changes
statistically (Figure 3).
Figure 2 The changes of triglyceride level.
Serum triglyceride level decreased from day 2 to day 14 with
significant difference (p<0.01). Maximum data of triglyceride
on day 2 was 1564.
Figure 3 The changes of HDL-C and LDL-C.
Serum levels of HDL-C and LDL-C showed no significant
changes from day 2 to day 14.
Correlations among glucose and lipid
biomarkers
There were significant negative correlation between
Triglyceride and HDL-C on day 2 (p<0.05), and between
triglyceride and LDL-C on day 2 (p<0.05) (Figure 4).
Figure 4 Correlations among triglyceride, HDL-C and LDL-C.
a) Triglyceride and HDL-C showed significant negative
correlation (p<0.05). b) Triglyceride and LDL-C showed
significant negative correlation (p<0.05).
RLP-C showed significant positive correlation with
Atherogenic Index and Triglyceride (p<0.01), significant
negative correlation with HDL (p<0.05), and no significant
correlation with LDL-C (Figures 5 and 6).
Figure 5 Correlations of RLP-C with atherogenic index (AI)
and triglyceride. a) Atherogenic index (AI) and RLP-C
showed significant positive correlation (p<0.01). b)
Triglyceride and RLP-C showed significant positive
correlation (p<0.01).
Endocrinology and Metabolism: Open Access
Vol.1 No.1:104
2017
4 This article is available from: http://www.imedpub.com/endocrinology-metabolism-open-access/
Figure 6 Correlations of RLP-C with HDL-C and LDL-C. a)
HDL-C and RLP-C showed significant negative correlation
(p<0.01). b) LDL-C and RLP-C showed no significant
correlation (n.p.).
Correlation of the data on day 2 and day 14 in triglyceride
and LDL-C/HDL-C ratio are shown in Figure 7. Both revealed
significant positive correlation (p<0.01).
Figure 7 Comparison between day 2 and day 14 in
triglyceride and LDL-C/HDL-C ratio. a) Triglyceride level on
day 14 decreased apparently from that on day 2. B) LDL-C/
HDL-C ratio on day 2 and 14 showed significant correlation
(p<0.01).
Discussion
We have investigated and reported concerning LCD in the
light of weight reduction, formular LCD diet, ketone bodies and
Morbus (M) value [19,20,21,22,24]. In current study, we
investigated the effect of LCD and the influence for glucose
and lipid metabolism in the patients with T2DM with high
degree of hypertriglycemia. We adopted super-LCD formula
including 42 g of carbohydrate per day [18,23], which is far
smaller dose from 130 g/day [13,34].
Average glucose and M value were apparently decreased
due to LCD for only 2 days, indicating rapid glucose lowering
efficacy of LCD. M value represents both elevated glucose level
and increased fluctuation of MAGE. The changes for numerical
level of M value are expressed larger than that of glucose, and
then the improvement of glucose variability would be easily
estimated. In type 1 diabetes mellitus (T1DM), glucose
variability and M value were investigated by continuous
glucose monitoring (CGM) or frequent sampling [35,36].
As the LCD become prevalent and developed, the research
focus would be the cardiovascular risk factors and the
relationship between glucose and lipids metabolism [1,37-39].
Triglyceride level in all 28 cases apparently decreased in only
12 days, and the regression curve showed y=0.127x+101.2,
indicating the degree of decrease. On contrast, HDL-C and LDL-
C showed no remarkable changes in only 12 days. When LCD is
continued for more than several months, HDL-C will be
increased [1,12,13].
LDL-C/HDL-C Ratio (L/H ratio) has been used for the
evaluation of arteriosclerosis. L/H ratio is especially important
index for diabetes and Met-S, because both states are
characteristic for elevated triglyceride, decreased HDL and
existing small dense LDL. L/H ratio value is said to correlate
with the development of plaque in the vessels.
The standard range of L/H ratio would be 2.0 and 1.5 is the
ideal value for patients with T2DM or hypertension. Target
point of L/H ratio would be 2.0 in primary prevention of
coronary heart disease (CHD), and 1.5 in secondary prevention
with the past history of CHD.
From the results of 28 cases, 7 cases (25%) showed L/H ratio
less than 2.0 on day 2, and only 1 case (3.6%) on day 14.
Current results would give the fundamental data of the
influence of LCD in short period for lipid metabolism and the
research direction in this field.
Remnant-like particles (RLPs) was isolated and investigated
as an atherogenic agent [40]. Through epidemiologic studies,
RLP-C levels showed associations with atherosclerosis,
cardiovascular disease (CVD), and coronary heart disease
(CHD) [41,42]. Furthermore, it would be an independent risk
factor for CVD in women, and provides significantly more
information than triglyceride [43,44].
RLP-C value has been elevated in T2DM [43-45]. RLP-C and
Triglyceride levels were significantly higher in diabetic
coronary artery disease (CAD) group than non-diabetic CAD
group on Diabetes Atherosclerosis Intervention Study (DAIS)
[46]. In addition, The AUCs of TG or RLP-C showed a
correlation with the AUCs of plasma insulin, with the
correlation for the insulin resistance index [47,48].
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From the results, RLP-C level correlated with atherogenic
index (AI), TG and HDL, but not with LDL-C. AI is calculated as
total-C-HDL-C/HDL-C, and is expressed for the tendency of
atherosclerosis with its standard range less than 4.0. Out of 28
cases, 9 cases showed AI less than 4.0.
This study included the patients whose triglyceride was
more than 250 mg/dL. Our current study would be useful for
research direction to clarify the pathophysiological mechanism
concerning glucose and lipid metabolism in T2DM.
Conclusion
In current study, we reported the efficacy of LCD for T2DM
by glucose and M value, and analyzed the relationship among
glucose, lipids such as RLP-C, triglyceride, HDL-C. LDL-C, L/H
ratio and AI. These findings would become the fundamental
data for clinical research and treatment of T2DM in the future.
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